The Evolving Management of Heart Failure: A Focus on Managed Care Recommendations
Jointly provided by
Impact Education, LLC    
This activity is supported by an independent educational grant from Novartis Pharmaceuticals Corporation.

You Are Invited to a LIVE Free CME/CNE/CPE Webcast:
The Evolving Management of Heart Failure: A Focus on Managed Care Recommendations

Live Webcast Dates

December 12, 2019 | 11:30am to 1:00pm ET - Click Here to Complete Your Evaluation and Download Your Certificate
January 28, 2020 | 11:30am to 1:00pm ET - Click Here to Register for This Date
February 4, 2020 | 12:30pm to 2:00pm ET - Click Here to Register for This Date

LEARN ABOUT:
  • Integrating novel therapies for HF into plan algorithms and utilization management strategies
  • Opportunities to overcome barriers to member access to care
  • Collaborative strategies for HF management including overseeing care transitions
EXPERT FACULTY
Akshay S. Desai, MD, MPH
Director, Heart Failure Disease Management Program, Advanced Heart Disease Section, Cardiovascular Division
Brigham and Women's Hospital
Associate Professor of Medicine
Harvard Medical School
Jeffrey D. Dunn, PharmD, MBA
(Formerly) Vice President, Clinical Strategy and Programs and Industry Relations
MagellanRx Management
John Fox, MD, MHA
Vice President of Clinical Transformation
Executive Medical Director, West Michigan ACO
Spectrum Health Systems
WHO SHOULD ATTEND?
  • Managed care pharmacy directors, clinical pharmacists, quality directors, medical directors
  • Pharmacy directors, specialty pharmacists, quality directors, care managers, registered nurses, and other managed care and payer organization professionals
PROGRAM OVERVIEW

The body of evidence supporting the use of emerging therapies in heart failure (HF) is constantly evolving. Recent findings among patients hospitalized with acute decompensated HF demonstrate the potential for a simpler treatment algorithm for inpatient care. In addition to negating the transition period necessary between therapies, hospitalized patients represent a captive audience and one that can be more easily educated and monitored for adherence. These and other considerations will be addressed by this activity including additional clinical trial results.

EDUCATIONAL OBJECTIVES

After completing the activity, participants should be better able to:
  • Integrate novel therapies for HF into plan algorithms and utilization management strategies in light of published evidence and provider inertia
  • Illustrate opportunities to overcome barriers to member access to care along with appropriate HF therapy within the current framework of health plan operations and infrastructure
  • Employ collaborative strategies for HF management, including overseeing care transitions, enlisting the input and support of a multidisciplinary team of health care providers
AGENDA
Opening Comments/Overview
Jeffrey D. Dunn, PharmD, MBA
Integrating Novel Therapies and Recent Evidence for HF into Plan Algorithms and Management Strategies
Akshay S. Desai, MD, MPH
Addressing Barriers for Appropriate HF Therapy and Interventions for Optimal Member Access to Care
John Fox, MD, MHA
Multidisciplinary Collaborations for Successful Care Transitions for Patients with HF
Jeffrey D. Dunn, PharmD, MBA
Faculty Idea Exchange
Audience Question and Answer Session

Key Takeaways and Closing Comments
ACCREDITATION INFORMATION
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Numbers
December 12, 2019 | JA4008162-9999-19-981-L01-P
January 28, 2020 | JA4008162-9999-20-982-L01-P
February 4, 2020 | JA4008162-9999-20-982-L01-P

Type of Activity: Application

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Hardware/Software Requirements
Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up.

Fee Information
There is no fee for this educational activity.

Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

If you have any questions, please call (215) 619-8812 or email info@impactedu.net.